Meeting
2017 ASCO Annual Meeting
HDAC11 as a candidate therapeutic target in multiple myeloma.
Authors
Allison Distler
H. Lee Moffitt Cancer Center, Tampa, FL
Allison Distler , Jason B. Brayer , Mark Meads , Eva Sahakian , John Joseph Powers , Melissa Alsina , Taiga Nishihori , Rachid C. Baz , Javier Pinilla-Ibarz , Eduardo M. Sotomayor , Kenneth H. Shain
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Plasma Cell Dyscrasia
Track
Hematologic Malignancies—Plasma Cell Dyscrasia
Sub Track
Multiple Myeloma
Citation
J Clin Oncol 35, 2017 (suppl; abstr 8029)
DOI
10.1200/JCO.2017.35.15_suppl.8029
Abstract #
8029
Poster Bd #
355
Abstract Disclosures
Similar Posters
Poster
2014 ASCO Annual Meeting
Effect of combination of proteasome inhibitor marizomib and immunomodulatory agent pomalidomide on synergistic cytotoxicity in multiple myeloma.
First Author: Dharminder Chauhan
Poster
2015 ASCO Annual Meeting
The AFFIRM Study: A multicenter phase 2 study of single-agent filanesib (ARRY-520) in patients with advanced multiple myeloma.
First Author: Sagar Lonial
Poster
2014 ASCO Annual Meeting
Effect of a novel agent, SL-401, targeting interleukin-3 receptor (IL-3R) on plasmacytoid dendritic cell (pDC)-induced myeloma cell growth and osteolytic bone disease.
First Author: Dharminder Chauhan
Poster
2013 ASCO Annual Meeting
Effect of a novel agent, SL-401, targeting interleukin-3 (IL-3)-receptor on plasmacytoid dendritic cell (pDC)-induced myeloma cell growth and drug resistance.
First Author: Dharminder Chauhan